Pfizer: Endometrial Neoplasms trials
The registry lists 13 Endometrial Neoplasms studies with Pfizer as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 9Phase 2 5Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerRecruitingNCT07578649Phase 3
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1
- A Study of PF-07260437 in Advanced or Metastatic Solid TumorsTerminatedNCT05067972Phase 1Results posted
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
- A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerTerminatedNCT01420081Phase 2Results posted
- A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2
- A Study of SGN-ALPV in Advanced Solid TumorsTerminatedNCT05229900Phase 1
- A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
- A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.TerminatedNCT04152018Phase 1